NNZ-2566: Could this prove helpful?

NNZ-2566 is a drug that intends to reduce brain inflammation. Much of its development has been funded by the military since it is hoped that this drug could reduce the effects of brain trauma. Now the Neuren Corporation is planning clinical trials with children with Rett syndrome and is currently developing the protocol for the trials.

If it helps, this drug could possibly also minimize the progressive effects of MECP2 Duplication Syndrome. Of course, this is a big jump of logic, but it does offer a glimmer of hoe on the horizon. If effective, it would not be a cure but could conceivably help minimize some of the symptoms or slow the progression of the syndrome. More information can be found in this recent news release.

This the 100th post on this blog!


One response to “NNZ-2566: Could this prove helpful?

  1. Pingback: Encouraging News about NNZ-2566 | MECP2 Duplication Syndrome Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s